Your session is about to expire
← Back to Search
Other
CT-868 for Type 1 Diabetes
Chula Vista, CA
Phase 1
Recruiting
Research Sponsored by Carmot Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
This trial will look into how a new drug affects people with Type 1 Diabetes to regulate their blood sugar.
Who is the study for?
Adults aged 18-65 with Type 1 diabetes, a BMI between 25.0 and 35.0, who have been managing their condition with an insulin pump or multiple daily injections for at least three months are eligible. Those with a history of cancer, significant medical conditions, surgical weight loss treatments, or uncontrolled diabetes cannot participate.
What is being tested?
The trial is testing the effects of CT-868 on blood sugar control in people with Type 1 Diabetes compared to a placebo and Victoza (a known diabetes medication). Participants will be randomly assigned to receive one of these treatments.
What are the potential side effects?
Possible side effects may include reactions at the injection site, low blood sugar levels (hypoglycemia), nausea, vomiting, diarrhea and potential allergic reactions to the medications used.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2014 Phase 4 trial • 368 Patients • NCT0200868215%
Nausea
11%
Decreased appetite
8%
Diarrhoea
6%
Lipase increased
1%
Diabetic ketoacidosis
1%
Sudden hearing loss
1%
Bronchitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Liraglutide
Sitagliptin
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: CT-868Experimental Treatment1 Intervention
SC injection of CT-868 Intervention
Group II: VictozaActive Control1 Intervention
SC injection of active comparator
Group III: PlaceboPlacebo Group1 Intervention
SC injection of placebo matching CT-868 dose
Find a Location
Closest Location:Carmot Clinical Research Unit 101· Chula Vista, CA
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Carmot Therapeutics, Inc.Lead Sponsor
7 Previous Clinical Trials
1,282 Total Patients Enrolled
Michael ElliottStudy DirectorCarmot Therapeutics, Inc.
5 Previous Clinical Trials
472 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have had surgery to help you lose weight.Your diabetes is not well controlled.Adults with Type 1 diabetes, whether male or female.Your body mass index (BMI) is between 25 and 35.You have been using an insulin pump or giving yourself multiple daily injections for at least 3 months.You have had type 1 diabetes for at least 3 years.You have had cancer in the past.You are between 18 and 65 years old.
Research Study Groups:
This trial has the following groups:- Group 1: Placebo
- Group 2: CT-868
- Group 3: Victoza
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.